TN2014000413A1 - Anti-baff-anti-il-17 bispecific antibodies - Google Patents
Anti-baff-anti-il-17 bispecific antibodiesInfo
- Publication number
- TN2014000413A1 TN2014000413A1 TNP2014000413A TN2014000413A TN2014000413A1 TN 2014000413 A1 TN2014000413 A1 TN 2014000413A1 TN P2014000413 A TNP2014000413 A TN P2014000413A TN 2014000413 A TN2014000413 A TN 2014000413A TN 2014000413 A1 TN2014000413 A1 TN 2014000413A1
- Authority
- TN
- Tunisia
- Prior art keywords
- baff
- bispecific antibodies
- sle
- pss
- psoriasis
- Prior art date
Links
Abstract
Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361768747P | 2013-02-25 | 2013-02-25 | |
PCT/US2013/036677 WO2013158577A1 (en) | 2012-04-20 | 2013-04-16 | Anti-baff-anti-il-17 bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2014000413A1 true TN2014000413A1 (en) | 2015-12-21 |
Family
ID=55447262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2014000413A TN2014000413A1 (en) | 2013-02-25 | 2014-09-30 | Anti-baff-anti-il-17 bispecific antibodies |
Country Status (1)
Country | Link |
---|---|
TN (1) | TN2014000413A1 (en) |
-
2014
- 2014-09-30 TN TNP2014000413A patent/TN2014000413A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12014502333A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
MX2015011957A (en) | Anti-tnf-anti-il-17 bispecific antibodies. | |
PH12015501994A1 (en) | Antibodies that bind il-23 | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
MX2022009875A (en) | Anti-variant fc-region antibodies and methods of use. | |
NZ739252A (en) | Monoclonal antibodies against bcma | |
PH12015501656B1 (en) | Anti-il-33 antibodies and use thereof | |
WO2014152157A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
TN2017000352A1 (en) | Antibodies to tau and uses thereof | |
MX2016006101A (en) | Il-17a conjugate and uses thereof. | |
WO2015013389A3 (en) | Anti-galectin-1 (gal1) monoclonal antibodies and fragments thereof for neutralizing gal1 | |
MX2018013072A (en) | Tl1a antibodies and uses thereof. | |
EP3573658A4 (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
EA201491471A1 (en) | COMPOSITION CONTAINING ANTIBODY AGAINST IL-17 | |
EP4023674A3 (en) | Anti-il-22r antibodies | |
MY174711A (en) | Novel anti-fc-gamma receptor iib antibodies and uses thereof | |
TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
TH1401006266A (en) | ANTI-BAFF-ANTI-IL-17 Bspecific Antibody | |
WO2014113431A3 (en) | Methods and compositions for targeting immunoglobulins | |
UA113080C2 (en) | A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF |